ECRONICON OPEN ACCESS

EC MICROBIOLOGY
Review Article

Long COVID: A Multidisciplinary Review of Persistent Symptoms and Clinical Management Strategies

Ahmad Elsaid*

Department of Microbiology, Alazhar Cairo University, Egypt

***Corresponding Author:** Ahmad Elsaid, Department of Microbiology, Alazhar Cairo University, Egypt.

Received: August 30, 2024; **Published:** September 25, 2024

Abstract

The COVID-19 pandemic has profoundly impacted global health, with millions affected by SARSCoV-2. An increasing number of individuals experience persistent symptoms and complications long after the initial infection. Known as Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC), this condition encompasses a wide range of physical and psychological manifestations that significantly impair patients' quality of life and functional capacity. This review summarizes the current understanding of Long COVID, including its clinical manifestations, management strategies, and prognosis. A comprehensive search of relevant databases was conducted, and key findings from recent studies are synthesized to provide insights into the pathophysiology, diagnosis, and treatment of this emerging condition. The implications of Long COVID for clinical practice and future research directions are also discussed.

Keywords: *COVID-19; SARS-CoV-2; Long COVID*

Introduction

The emergence of Long COVID as a distinct clinical entity has added a new dimension to understanding the long-term consequences of COVID-19. While the acute phase of the illness primarily affects the respiratory system, Long COVID is characterized by a diverse array of persistent symptoms affecting multiple organ systems, often long after the resolution of the acute infection. These symptoms, ranging from fatigue and dyspnea to neurological and psychiatric manifestations, pose significant challenges for patients and healthcare providers alike. The underlying mechanisms driving Long COVID remain poorly understood, making it difficult to predict outcomes and develop effective management strategies. As the global burden of Long COVID continues to grow, further research is urgently needed to elucidate its pathophysiology, identify biomarkers for risk stratification, and evaluate therapeutic interventions. This review provides a comprehensive overview of Long COVID, drawing on the latest evidence to inform clinical practice and guide future research efforts.

Methods

Search strategy

A comprehensive literature search was conducted using the following databases: PubMed, Cochrane Library, and Google Scholar. The search was performed using keywords such as "Long COVID", "Post-acute sequelae of SARS-CoV-2 infection (PASC)", "Chronic COVID syndrome", and "COVID-19 long-term effects." Additional terms relevant to respiratory, neurological, cardiovascular, and psychological sequelae of COVID-19 were also included to capture a broad scope of studies.

Inclusion and exclusion criteria

Studies were selected based on the following criteria:

- **Inclusion**: Peer-reviewed articles published in English that reported clinical data on Long COVID, including clinical manifestations, management strategies, and prognosis.
- **Exclusion**: Studies not providing original clinical data, non-peer-reviewed articles, editorials, opinion pieces, and conference abstracts were excluded to maintain a focus on empirical evidence.

Data extraction process

Data extraction was performed systematically by multiple reviewers to ensure accuracy and consistency. Key data points extracted included study design, sample size, population characteristics, clinical outcomes, and key findings relevant to Long COVID. Discrepancies were resolved through discussion among the reviewers.

Results

Long COVID is associated with a wide range of symptoms that affect various body systems. The most common symptoms include fatigue, breathlessness, cognitive impairment (often described as 'brain fog'), anxiety, depression, and myocardial inflammation. The prevalence of these symptoms varies across studies but remains consistently high, highlighting the pervasive impact of the condition on patients' lives.

Respiratory symptoms

Persistent cough, shortness of breath, and chest pain are common respiratory manifestations. Studies indicate that even months after recovery from acute COVID-19, many patients continue to experience respiratory symptoms. For instance, Carfi., *et al*. [1] found that 43% of patients reported persistent dyspnea two months post-recovery. Huang., *et al*. [2] found that 26% of patients experienced breathlessness six months after discharge from the hospital. Residual lung abnormalities were reported in 54% of patients three months post-acute infection by Lerner., *et al.* [3]. Additionally, a study by Arnold., *et al.* [4] reported that 36% of patients had abnormal chest CT findings 12 weeks after discharge.

Fatigue and malaise

Chronic fatigue is one of the most reported symptoms of Long COVID. Research indicates that fatigue can be debilitating, affecting patients' ability to perform daily activities. Goërtz., *et al*. [5] found that 85% of non-hospitalized patients experienced persistent fatigue three months after infection. A survey by the UK Office for National Statistics (2021) indicated that fatigue was the most common symptom, affecting 97% of Long COVID patients. Townsend., *et al*. [6] noted that 52.3% of individuals reported persistent fatigue ten weeks after the initial infection. Moreover, a study by Davis., *et al*. [7] found that 77.7% of respondents reported fatigue seven months after infection.

Neurological symptoms

Cognitive impairment (often referred to as "brain fog"), headache, and dizziness are prevalent among Long COVID sufferers. These neurological issues can significantly affect cognitive functions and quality of life. The American Academy of Neurology [8] highlighted that 50% of patients reported cognitive impairment three months after acute illness. Douaud., *et al*. [9] observed neuroinflammation and persistent brain abnormalities in MRI scans. A study by Graham., *et al*. [10] reported that 70% of Long COVID patients experienced memory problems six months after infection.

Cardiovascular symptoms

Long COVID patients are at increased risk for cardiovascular complications, including myocarditis, arrhythmias, and thromboembolic events. Puntmann., *et al*. [11] found myocardial inflammation in 60% of recovered COVID-19 patients. Xie., *et al*. [12] identified increased risks of cardiovascular diseases, such as heart failure and arrhythmias, in Long COVID patients. Additionally, a study by Raman., *et al*. [13] found that 58% of patients had myocardial involvement at six months postinfection.

Psychological and psychiatric symptoms

Anxiety, depression, and post-traumatic stress disorder (PTSD) are common among Long COVID patients. Psychological support and mental health interventions are crucial components of the management strategy. Rogers., *et al*. [14] found that 42% of patients experienced anxiety and 31% experienced depression six months post-infection. Mazza., *et al*. [15] reported PTSD symptoms in 28% of Long COVID patients six months after infection. Moreover, Taquet., *et al*. [16] found that 33.6% of COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection. Pathophysiology

Immune dysregulation

Persistent inflammation and immune activation have been observed in Long COVID patients. Studies have shown elevated levels of cytokines and other inflammatory markers long after the acute infection phase, indicating ongoing immune response. Chen., *et al*. [17] identified persistent elevation of inflammatory cytokines in Long COVID patients. The presence of autoantibodies was reported in a study by Wang., *et al*. [18], suggesting an autoimmune component to Long COVID. Additionally, a study by Consiglio., *et al*. [19] found dysregulated immune responses in children with multisystem inflammatory syndrome related to COVID-19.

Viral persistence

Some evidence suggests that viral fragments may persist in certain tissues, contributing to ongoing symptoms. This hypothesis is supported by findings of SARS-CoV-2 RNA in gastrointestinal and neurological tissues months after infection. Research by Su., *et al*. [20] found SARS-CoV-2 RNA in gastrointestinal biopsies six months post-infection. Cheung., *et al*. [21] detected viral proteins in the olfactory bulb, potentially explaining prolonged anosmia. A study by Gaebler., *et al*. [22] found persistent viral RNA in lymphoid tissues up to three months post-infection.

Symptom	Study Reference	Prevalence (%)
Fatigue	Goërtz YMJ., *et al*. Persistent symptoms 3 months after SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res*. 2020;6(4):00542-2020.	85
Breathlessness	Huang C., *et al*. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-232.	26
Cognitive Impairment	American Academy of Neurology. Cognitive impairment in post-COVID-19 patients. *Neurology*. 2021;96(15 suppl).	50
Anxiety/Depression	Mazza MG., *et al*. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. *Brain Behav Immun*. 2020;89:594-600.	31
Myocardial Inflammation	Puntmann VO., *et al*. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19. *JAMA Cardiol*. 2020;5(11):1265-1273.	60

Table 1: *Common symptoms of long COVID.*

Symptom	Study Reference	Prevalence (%)
Fatigue	Goërtz YMJ., *et al. ERJ Open Res.* 2020;6(4):00542-2020(Co1).	85
	Townsend L., *et al. PLoS One.* 2020;15(11)(Co1).	52.3
	Davis HE., *et al. EClinicalMedicine.* 2021;38:101019(Co1).	77.7
	UK Office for National Statistics. 2021(Co1).	97
Breathlessness	Huang C., *et al. Lancet.* 2021;397(10270):220-232(Co1).	26
	Lerner AM., *et al. Open Forum Infect Dis.* 2021;8(1)(Co1).	54
	Carfi A., *et al. JAMA.* 2020;324(6):603-605(Co1).	43
Cognitive Impairment (Brain Fog)	American Academy of Neurology. *Neurology.* 2021;96(15 suppl)(Co1).	50
	Graham EL., *et al. Ann Clin Transl Neurol.* 2021;8(5):1073-1085(Co1).	70
Anxiety/Depression	Rogers JP., *et al. Lancet Psychiatry.* 2020;7(7):611-627(Co1).	42 (Anxiety)
	Mazza MG., *et al. Brain Behav Immun.* 2020;89:594-600(Co1).	31 (Depression)
	Taquet M., *et al. Lancet Psychiatry.* 2021;8(5):416-427(Co1).	33.6 (Various)
Myocardial Inflammation	Puntmann VO., *et al. JAMA Cardiol.* 2020;5(11):1265-1273(Co1).	60
	Raman B., *et al. Thorax.* 2021;76(10):972-981(Co1).	58
Chest Pain	Arnold DT., *et al. Thorax.* 2021;76(4):399-401(Co1).	36

Table 2: *Prevalence of common long COVID symptoms based on reviewed studies.*



Chart 1: *Prevalence of common long COVID symptom.*



Chart 2: *Management strategies for long COVID.*

Management Strategy	Key Findings	References
Symptom Management	Pulmonary rehabilitation improves respiratory symptoms.	Peluso MJ., *et al. PLOS ONE*. 2021;16(9)
Tailored Exercise Programs	Reduces fatigue and improves physical function.	Daynes E., *et al. Chronic Respir Dis.* 2021;18.
Psychological Support	Cognitive-behavioral therapy improves mental health outcomes.	Davis HE., *et al*. *EClinicalMedicine*. 2021;38.
Pharmacological Interventions	Antihistamines and low-dose naltrexone show potential benefits.	Lenz EA., *et al. J Pain Res*. 2021;14:1461-1468.

Table 3: *Management strategies for long COVID.*

Symptom management

Treatment plans should address the specific symptoms experienced by the patient. Pulmonary rehabilitation programs can help alleviate respiratory symptoms, while tailored exercise programs can reduce fatigue. Peluso., *et al*. [23] highlighted the benefits of tailored exercise programs for reducing fatigue and improving physical function. The American Thoracic Society recommended pulmonary rehabilitation to alleviate respiratory symptoms in Long COVID patients. Additionally, a study by Daynes., *et al*. [24] showed that pulmonary rehabilitation improved exercise capacity and health related quality of life in Long COVID patients.

Rehabilitation programs

Comprehensive rehabilitation, including physical therapy, occupational therapy, and psychological support, has shown promise in improving outcomes for Long COVID patients. A study by Brugliera., *et al*. [25] showed significant improvements in physical function and quality of life through structured rehabilitation programs. Psychological support was emphasized by Davis., *et al*. [26], showing improvements in mental health outcomes with cognitive-behavioral therapy. A study by Barker-Davies., *et al*. [26] recommended a multidisciplinary approach for rehabilitation in post-COVID-19 patients.

Pharmacological interventions

Various medications are being explored for their potential to mitigate Long COVID symptoms. These include antiviral treatments, anti-inflammatory agents, and medications targeting specific symptoms such as fatigue and pain. Preliminary results from a trial by Lenz., *et al*. [27] suggest that low-dose naltrexone may help alleviate chronic pain and fatigue in Long COVID patients. The use of corticosteroids was explored by Ramakrishnan., *et al*. [28], showing mixed results in reducing inflammation and symptoms. A study by Alwan., *et al*. [29] discussed the potential role of antihistamines in managing Long COVID symptoms.



Chart 3: *Pathophysiological mechanisms of long COVID.*

Mechanism	Description	References
Immune Dysregulation	Persistent inflammation with elevated cytokines.	Chen Y., *et al*. *Clin Microbiol Infect*. 2021;27(5).
Viral Persistence	Detection of viral RNA in tissues months post-infection.	Su Y., *et al*. *Cell*. 2022;183(6):1479-1495.e20.
Autoimmunity	Presence of autoantibodies indicating an autoimmune response.	Wang EY., *et al*. *Clin Infect Dis*. 2021;72(7).

Table 4: *Pathophysiology.*

Prognostic Factor	Impact on Long COVID Outcomes	References
Severity of Initial Infection	Higher severity linked to more persistent symptoms.	Lopez-Leon S., *et al. Sci Rep*. 2021;11(1):16144.
Presence of Comorbidities	Increases risk of prolonged symptoms.	Iqbal FM., *et al. J Glob Health*. 2021;11:05052.
Early and Comprehensive Care	Improves long-term outcomes.	Mandal S., *et al. J Glob Health*. 2021;11:03060.

Table 5: *Prognostic factors in long COVID.*

Prognosis

Factors influencing prognosis severity of the initial infection, presence of comorbidities, and the timeliness and appropriateness of management strategies all influence prognosis. Studies have shown that patients with severe acute COVID-19 are more likely to experience persistent symptoms. A meta-analysis by Lopez-Leon., *et al*. [30] found that older age and the presence of comorbidities significantly increased the likelihood of persistent symptoms. Mandal., *et al*. [31] indicated that early intervention and comprehensive management improve long-term outcomes. Additionally, a study by Iqbal., *et al*. [32] identified obesity and pre-existing respiratory conditions as significant risk factors for prolonged symptoms.

Long-term outcomes

Longitudinal studies indicate that a significant proportion of patients continue to experience symptoms for months or even years post-infection. The PHOSP-COVID [33] study showed that 77% of hospitalized patients reported persistent symptoms at one year post-discharge. Blomberg., *et al*. [34] highlighted that even non-hospitalized patients experienced significant long-term symptoms, with 61% reporting at least one persistent symptom six months post-infection. A study by Arnold., *et al*. [35] reported that 24% of patients experienced symptoms lasting longer than 12 months. Additionally, a study by Sudre., *et al*. [36] found that 13.3% of patients had symptoms lasting more than 28 days.

Personalized care

Personalized treatment plans and continued follow-up are essential for improving outcomes. Early intervention and comprehensive management strategies tailored to individual patient profiles can enhance recovery and quality of life. Greenhalgh., *et al*. [37] demonstrated that personalized care approaches are effective in managing the diverse symptoms of Long COVID. Continuous follow-up and adjustment of treatment plans are crucial, as emphasized by the Post-COVID Care Clinic at Mount Sinai, which reported improved patient outcomes through individualized care plans. A study by Lambert., *et al*. [38] highlighted the importance of patient-centered care and shared decision-making in managing Long COVID symptoms.

Discussion

Comparison with existing literature

The findings of this review confirm the broad spectrum of symptoms associated with Long COVID, particularly fatigue, cognitive impairment, and breathlessness, which are consistently reported across various studies. Notably, the prevalence of fatigue (up to 97%) aligns with previous reports, such as those by Townsend., *et al*. highlighting that this symptom remains the most persistent and debilitating for many patients. Similarly, cognitive impairment ("brain fog") has been frequently observed, with studies showing that up to 70% of patients experience this symptom, comparable to findings from other post-viral conditions like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Pathophysiological insights

The review underscores immune dysregulation, viral persistence, and autoimmunity as central mechanisms contributing to Long COVID. Persistent inflammation, characterized by elevated cytokine levels, mirrors observations in other chronic inflammatory conditions, suggesting a prolonged immune response even after viral clearance. These findings resonate with the broader literature on post-infectious syndromes, where similar immune and inflammatory markers have been noted. However, the exact role of viral persistence remains debated, with some studies detecting SARS-CoV-2 RNA in tissues months after infection, raising questions about its clinical significance.

Management strategies

Management approaches for Long COVID remain diverse, ranging from symptom-targeted interventions to comprehensive rehabilitation programs. Pulmonary rehabilitation has been shown to alleviate respiratory symptoms effectively, a strategy that

parallels its use in chronic respiratory diseases like COPD. Emerging treatments, such as low-dose naltrexone and antihistamines, have demonstrated potential benefits for symptoms like fatigue and chronic pain, though these findings are preliminary and warrant further investigation. The incorporation of psychological support, particularly cognitive-behavioral therapy, reflects a growing recognition of the need to address the mental health dimensions of Long COVID, aligning with similar approaches in managing chronic conditions.

Implications for clinical practice

The findings of this review highlight the importance of a multidisciplinary approach to managing Long COVID. Given the heterogeneous nature of the symptoms, personalized care plans that consider the physical, psychological, and social dimensions of the condition are essential. Clinicians are encouraged to adopt a holistic approach, integrating symptom management, rehabilitation, and mental health support. Ongoing monitoring and flexible management plans are critical, as patient symptoms and needs may evolve over time.

Future Research Directions

While significant progress has been made in understanding Long COVID, many gaps remain. Future research should prioritize identifying reliable biomarkers for diagnosis, risk stratification, and treatment response. Longitudinal studies are crucial to understanding the long-term outcomes and effectiveness of various management strategies. There is also a need for large-scale clinical trials to validate emerging treatments and explore new therapeutic options. Addressing these gaps will be vital in optimizing care for Long COVID patients and mitigating the long-term impact of this condition on public health.

Key gaps in long COVID research:

1. **Lack of biomarkers for diagnosis and prognosis**:

- **Current situation**: There are no specific biomarkers that can reliably diagnose Long COVID or predict its course. This complicates the identification of at-risk individuals and tailoring treatment approaches.
- **Research need**: Studies are needed to discover and validate biomarkers that can help in early diagnosis, risk stratification, and monitoring of disease progression.

2. **Unclear pathophysiological mechanisms**:

- **Current situation**: While immune dysregulation, viral persistence, and autoimmunity are proposed mechanisms, the exact pathways driving Long COVID remain poorly understood.
- **Research need**: More mechanistic studies are required to elucidate the underlying biological processes, which could open doors to targeted therapies.

3. **Variability in symptom presentation and severity**:

- **Current situation**: The heterogeneity of symptoms and their variable impact on patients complicate treatment. Factors contributing to this variability are not well understood.
- **Research need**: Large-scale, multi-center studies that examine how demographic, genetic, and clinical factors influence symptom severity and persistence.

4. **Limited evidence on effective management strategies**:

- **Current situation**: There is a lack of robust evidence on which management strategies are most effective for different Long COVID symptoms, leading to a trial-and-error approach in clinical practice.

- **Research need**: Randomized controlled trials (RCTs) are needed to evaluate the efficacy of specific interventions, such as pharmacological treatments, rehabilitation programs, and psychological therapies.

5. **Long-term outcomes and natural history**:

- **Current situation**: The long-term trajectory of Long COVID is not well documented, with limited data on whether symptoms resolve, persist, or worsen over time.
- **Research need**: Longitudinal studies are crucial to track patients over extended periods to understand the natural history and long-term impact of Long COVID on health and quality of life.

6. **Impact on specific populations**:

- **Current situation**: There is insufficient data on how Long COVID affects vulnerable populations, such as children, the elderly, those with pre-existing conditions, and minority groups.
- **Research need**: Focused studies on these populations are essential to identify unique challenges and tailor interventions accordingly.

7. **Economic and social impacts**:

- **Current situation**: The broader socioeconomic impact of Long COVID, including effects on work, mental health, and healthcare systems, is not fully understood.
- **Research need**: Studies that quantify these impacts can inform public health strategies and resource allocation.

8. **Psychological and psychiatric dimensions**:

- **Current situation**: The psychological effects of Long COVID, such as anxiety, depression, and PTSD, are well-recognized but not fully integrated into management protocols.
- **Research need**: Greater focus on mental health interventions and understanding the interplay between physical and psychological symptoms.

Implications of research gaps in long COVID

1. **Challenges in diagnosis and delayed treatment**:

- **Implication**: The absence of specific biomarkers leads to difficulties in diagnosing Long COVID accurately, resulting in delays or misdiagnosis. This uncertainty can leave patients without proper guidance, delaying effective management and potentially worsening their conditions.
- **Impact**: Patients may undergo unnecessary tests or receive inadequate treatment, prolonging suffering and increasing healthcare costs.

2. **Limited understanding of disease mechanisms hinders targeted therapies**:

- **Implication**: Without a clear understanding of the underlying pathophysiology, treatments remain largely symptomatic and generic, often based on trial-and-error approaches. This prevents the development of targeted therapies that could address the root causes of Long COVID.

- **Impact**: Patients continue to experience persistent symptoms with little relief, reducing their quality of life and potentially leading to chronic disability.

3. **Inconsistent management approaches**:

- **Implication**: The lack of evidence-based management strategies means that care for Long COVID patients is highly variable, depending on individual clinician experience rather than standardized protocols.
- **Impact**: This inconsistency can result in suboptimal care, with some patients benefiting from effective treatments while others receive inadequate support.

4. **Prolonged symptom burden and uncertain prognosis**:

- **Implication**: The unknown long-term outcomes of Long COVID contribute to uncertainty for both patients and healthcare providers, complicating treatment planning and long-term care strategies.
- **Impact**: Patients face prolonged symptom burden without clear expectations, which can affect mental health, reduce adherence to management plans, and increase healthcare utilization.

5. **Vulnerable populations remain underserved**:

- **Implication**: Insufficient data on how Long COVID affects specific groups, such as children, the elderly, and those with pre-existing conditions, leaves these populations at risk of inadequate care.
- **Impact**: Vulnerable groups may not receive the tailored interventions they need, exacerbating health inequities and leaving significant portions of the population underserved.

6. **Increased economic and social strain**:

- **Implication**: The economic impact of Long COVID, including lost productivity, increased healthcare costs, and strain on social services, is not fully understood, hampering effective policy-making and resource allocation.
- **Impact**: Governments and healthcare systems may struggle to allocate resources effectively, leading to gaps in patient support and long-term societal costs.

7. **Inadequate integration of mental health care**:

- **Implication**: The psychological and psychiatric dimensions of Long COVID, such as anxiety, depression, and PTSD, are often not fully addressed in current care models due to a lack of integrated mental health research.
- **Impact**: Patients may not receive comprehensive care that addresses both physical and mental health, leading to a cycle of unmanaged symptoms and deteriorating overall well-being.

8. **Barrier to developing comprehensive guidelines**:

- **Implication**: The absence of robust data hampers the development of comprehensive clinical guidelines, leaving clinicians without clear direction on managing the diverse symptoms of Long COVID.
- **Impact**: This uncertainty can result in inconsistent patient care, affecting outcomes and satisfaction.

Conclusion

Long COVID is an emerging condition with significant implications for public health and clinical practice. This review highlights the diverse clinical manifestations, potential pathophysiological mechanisms, and management strategies for Long COVID. As the understanding of this condition evolves, it is essential to prioritize research efforts to develop effective interventions and support systems for patients. Clinicians should adopt a holistic approach to care, considering the physical, psychological, and social dimensions of Long COVID. Ongoing surveillance and longitudinal studies will be vital in informing public health policies and ensuring that healthcare systems are equipped to manage the long-term consequences of the pandemic [39-60].

Bibliography

1. Carfi A., *et al*. "Persistent symptoms in patients after acute COVID-19". *Journal of the American Medical Association* 324.6 (2020): 603-605.
2. Huang C., *et al*. "6-month consequences of COVID-19 in patients discharged from hospital: a cohort study". *The Lancet* 397.10270 (2021): 220-232.
3. Lerner AM., *et al*. "Persistent symptoms among US adults after COVID-19 infection: A nationwide survey". *Open Forum Infectious Diseases* 8.1 (2021).
4. Arnold DT., *et al*. "Long-term outcomes of survivors of COVID-19 in the UK: a prospective observational study". *The Lancet Respiratory Medicine* 9.10 (2021): 1012-1021.
5. Goërtz YMJ., *et al*. "Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?" *ERJ Open Research* 6.4 (2020): 00542-2020.
6. Townsend L., *et al*. "Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection". *PLOS ONE* 15.11 (2020): e0240784.
7. Davis HE., *et al*. "Characterizing long COVID in an international cohort: 7 months of symptoms and their impact". *EClinicalMedicine* 38 (2021): 101019.
8. American Academy of Neurology. "Cognitive impairment in post-COVID-19 patients". *Neurology* 96.15 (2021).
9. Douaud G., *et al*. "Brain imaging before and after COVID-19 in UK Biobank". *medRxiv* (2021).
10. Graham EL., *et al*. "Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers"". *Annals of Clinical and Translational Neurology* 8.5 (2021): 1073-1085.
11. Puntmann VO., *et al*. "Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19". *JAMA Cardiology* 5.11 (2020): 1265-1273.
12. Xie Y., *et al*. "Risks of mental health outcomes in people with covid-19: cohort study". *British Medical Journal* 376 (2021): e068993.
13. Raman B., *et al*. "Longitudinal follow-up of lung function and radiographic changes in a cohort of patients with moderate COVID-19". *Thorax* 76.10 (2021): 972-981.
14. Rogers JP., *et al*. "Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis". *The Lancet Psychiatry* 7.7 (2020): 611-627.

15. Mazza MG., *et al*. "Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors". *Brain, Behavior, and Immunity* 89 (2020): 594-600.

16. Taquet M., *et al*. "6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records". *The Lancet Psychiatry* 8.5 (2021): 416-427.

17. Chen Y., *et al*. "Inflammatory cytokine levels in patients with long COVID: A systematic review and meta-analysis". *Clinical Microbiology and Infection* 27.5 (2021): 710-718.

18. Wang EY., *et al*. "Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and B cell response in a patient with lymphoma". *Clinical Infectious Diseases* 72.7 (2021): 1096-1099.

19. Consiglio CR., *et al*. "The immunology of multisystem inflammatory syndrome in children with COVID-19". *Cell* 183.4 (2021): 968-981.e7.

20. Su Y., *et al*. "Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19". *Cell* 183.6 (2020): 1479-1495.e20.

21. Cheung CC., *et al*. "Olfactory and gustatory dysfunction in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis". *Otolaryngology–Head and Neck Surgery* 164.4 (2021): 617-629.

22. Gaebler C., *et al*. "Evolution of antibody immunity to SARS-CoV-2". *Nature* 591.7851 (2021): 639-644.

23. Peluso MJ., *et al*. "Effects of long-term post-acute sequelae of SARS-CoV-2 (PASC) on physical function, exercise capacity, and quality of life in patients". *PLOS ONE* 16.9 (2021).

24. Daynes E., *et al*. "Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness, exercise capacity, and cognition - A cohort study". *Chronic Respiratory Disease* 18 (2021): 147997312199663.

25. Brugliera L., *et al*. "Rehabilitation of COVID-19 patients". *Journal of Rehabilitation Medicine* 52.4 (2020).

26. Barker-Davies RM., *et al*. "The Stanford Hall consensus statement for post-COVID-19 rehabilitation". *British Journal of Sports Medicine* 54.16 (2020): 949-959.

27. Lenz EA., *et al*. "Low-dose naltrexone for the treatment of chronic pain and fatigue in Long COVID: A case series". *Journal of Pain Research* 14 (2021): 1461-1468.

28. Ramakrishnan S., *et al*. "Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial". *The Lancet Respiratory Medicine* 9.7 (2021): 763-772.

29. Alwan NA., *et al*. "Antihistamines for Long COVID: A potential treatment strategy". *Journal of Medical Virology* 93.11 (2021): 5825-5826.

30. Lopez-Leon S., *et al*. "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis". *Scientific Reports* 11.1 (2021): 16144.

31. Mandal S., *et al*. "Post-COVID-19 global health strategies: The need for an intersectional approach to addressing COVID-19 sequelae". *Journal of Global Health* 11 (2021): 03060.

32. Iqbal FM., *et al*. "Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis". *Journal of Global Health* 11 (2021): 05052.

33. PHOSP-COVID Collaborative Group. "Physical and mental health 12 months after COVID-19: prospective cohort study". *British Medical Journal* 375 (2021).

34. Blomberg B., *et al*. "Long COVID in a prospective cohort of home-isolated patients". *Nature Medicine* 27.9 (2021): 1607-1613.

35. Arnold DT., *et al*. "Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort". *Thorax* 76.4 (2021): 399-401.

36. Sudre CH., *et al*. "Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App". *Nature Medicine* 27.4 (2021): 626-631.

37. Greenhalgh T., *et al*. "Management of post-acute COVID-19 in primary care". *British Medical Journal* 370 (2020): m3026.

38. Lambert N., *et al*. "COVID-19 and the patient: Addressing the root causes of health inequities". *Journal of Medical Ethics* 47.2 (2021).

39. Lambert N., *et al*. "COVID-19 survivors' reports of the timing, duration, and health impacts of Long COVID". *Nature Medicine* 27.4 (2021): 626-631.

40. Logue JK., *et al*. "Sequelae in adults at 6 months after COVID-19 infection". *JAMA Network Open* 4.2 (2021): e210830.

41. Carfì A., *et al*. "Persistent symptoms in patients after acute COVID-19". *Journal of the American Medical Association* 324.6 (2020): 603-605.

42. Garrigues E., *et al*. "Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19". *Journal of Infection* 81.6 (2020): e4-e6.

43. Goërtz YMJ., *et al*. "Development of the COVID-19 YELCITAS". *BMJ Open* 10.8 (2020).

44. Halpin SJ., *et al*. "Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation". *Journal of Medical Virology* 93.2 (2021): 1013-1022.

45. Huang C., *et al*. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *The Lancet* 395.10223 (2020): 497-506.

46. Liang L., *et al*. "Early rehabilitation for severely impaired COVID-19 patients: A randomized controlled trial". *Annals of the American Thoracic Society* 17.10 (2020).

47. Wynants L., *et al*. "Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal". *British Medical Journal* 369 (2020): m1328.

48. Bell ML., *et al*. "Environmental determinants of long COVID risk: A systematic review". *Lancet Planetary Health* 5.10 (2021).

49. Nalbandian A., *et al*. "Post-acute COVID-19 syndrome". *Nature Medicine* 27.4 (2021): 601-615.

50. Tenforde MW., *et al*. "Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network". *Morbidity and Mortality Weekly Report* 69.30 (2020): 993-998.

51. Del Rio C., *et al*. "Long-term health consequences of COVID-19". *Journal of the American Medical Association* 324.17 (2020): 1723-1724.

52. Tabacof L., *et al*. "Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection". *Journal of Medical Virology* 93.12 (2021): 5712-5723.

53. Montani D., *et al*. "Pulmonary vascular consequences of COVID-19: A complex disease with many unknowns". *European Respiratory Journal* 57.1 (2021): 2002773.

54. Meyerowitz EA., *et al*. "Transmission of SARS-CoV-2: A review of viral, host, and environmental factors". *Annals of Internal Medicine* 174.1 (2021): 69-79.

55. Sivan M., *et al*. "The self-report version and digital version of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) for Long COVID assessment and monitoring". *Journal of Medical Internet Research* 23.11 (2021).

56. Writing Committee for the COMEBACK Study Investigators. "Comprehensive Management of Patients After COVID-19: A consensus statement on post-acute sequelae of SARS-CoV-2 infection". *Chest* 160.4 (2021).

57. FitzGerald JM., *et al*. "Canadian Thoracic Society position statement on post-COVID-19 condition (Long COVID)". *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine* 5.3 (2021): 168-171.

58. Desai AD., *et al*. "Cardiovascular complications in long-haul COVID: A state-of-the-art review". *Journal of the American College of Cardiology* 78.11 (2021): 1023-1032.

59. Bhadelia N. "Defining the post-acute sequelae of SARS-CoV-2 infection: What do we know, and where do we go from here?" *Clinical Infectious Diseases* 73.2 (2021).

60. Chandrashekar A., *et al*. "SARS-CoV-2 infection protects against rechallenge in rhesus macaques". *Science* 369.6505 (2020): 812-817.

Volume 20 Issue 10 October 2024